How the Endocannabinoid System Drives Obesity Through Both Brain Appetite Circuits and Fat Cell Activity | Research

The takeaway

Research shows endocannabinoids promote obesity through a dual mechanism: stimulating appetite in the brain and directly promoting fat storage in adipose tissue, making CB1 receptor blockers a promising anti-obesity treatment.

Read this if you want to understand the science behind how the cannabinoid system affects body weight and fat storage.

CB1 activation promotes fat storage directly in adipose tissue, not just through increased appetite

What the researchers found

This review detailed how the endocannabinoid system contributes to obesity through two parallel mechanisms. In the brain, CB1 receptors in the hypothalamus and mesolimbic system regulate appetite by modulating hunger signals and the reward value of food. CB1 activation stimulates food intake, particularly of palatable foods, through dopamine release in the nucleus accumbens.

In peripheral tissues, CB1 receptors were found to be present in adipose tissue and the gastrointestinal system. In fat cells, CB1 activation directly stimulates lipogenesis (fat production). Animal models showed that genetically obese animals have permanently overactive endocannabinoid systems, which may help maintain obesity.

CB1 blockers showed dual benefits: increasing adiponectin production in fat cells (which promotes fatty acid burning) and reducing appetite centrally. CB1 receptors were also found to be upregulated in fat cells from obese animals.

Why it matters

The discovery that endocannabinoids act on fat cells directly, not just on brain appetite circuits, changed the understanding of how the cannabinoid system contributes to obesity. It also explained why CB1 blockers might produce weight loss effects beyond simple appetite reduction.

The numbers in context

CB1 receptors found in hypothalamus, mesolimbic system, adipose tissue, and GI tract. CB1 activation stimulates lipogenesis in fat cells. CB1 blockers increase adiponectin production. CB1 is upregulated in obese animal adipocytes. Genetically obese animals show chronic endocannabinoid overactivation.

How the study worked

Narrative review examining evidence from molecular biology, animal models of obesity, and early clinical data on the role of CB1 receptors in central appetite regulation and peripheral energy metabolism. Covered both brain and adipose tissue endocannabinoid signaling.

What this study cannot tell us

Much evidence came from animal models that may not fully translate to humans. The review was published before long-term clinical trial data on CB1 blockers was available. The complexity of endocannabinoid signaling means blocking CB1 affects many systems beyond appetite and fat storage.

How to read the evidence

Review synthesizing molecular, animal, and early clinical evidence. Strong mechanistic support but clinical applications were still developing at publication.

When this study was published

Published in 2005. The CB1 blocker rimonabant was later approved in Europe (2006) but withdrawn (2008) due to depression and suicidal ideation side effects.

The bigger picture

This research contributed to the development of rimonabant (Acomplia), the first CB1 antagonist approved for obesity treatment. While rimonabant was later withdrawn due to psychiatric side effects, the underlying science about endocannabinoid involvement in obesity continues to inform drug development for metabolic disorders.

Questions still open

Can CB1 blockers be developed that target peripheral fat tissue without crossing the blood-brain barrier, potentially avoiding psychiatric side effects? Does chronic cannabis use affect long-term body weight through these mechanisms?

Common questions

Does the endocannabinoid system cause weight gain beyond just increasing appetite?

Yes. This review shows CB1 receptors on fat cells directly stimulate lipogenesis (fat production). So endocannabinoids promote weight gain through both increased eating and increased fat storage, independent of food intake.

Why do some cannabis users gain weight while others stay thin?

The relationship is complex. While endocannabinoid activation promotes appetite and fat storage, chronic cannabis exposure may lead to tolerance of these effects. This review focused on the endocannabinoid system's role in obesity rather than the effects of exogenous cannabis use.

Read the original research

The endocannabinoid system and the treatment of obesity.

Annals of medicine, 37(4), 270-5

View on PubMed ↗

Citation

Pagotto, Uberto; Vicennati, Valentina; Pasquali, Renato. (2005). The endocannabinoid system and the treatment of obesity.. Annals of medicine, 37(4), 270-5.